Zhitong Finance App News, Shanghai Pharmaceutical (02607) announced that from January to September 2026, the company achieved operating revenue of 222,964 billion yuan (currency is RMB, same below), an increase of 3.67% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 18.989 billion yuan, an increase of 4.54% over the previous year; the pharmaceutical business achieved sales revenue of 203,975 billion yuan, an increase of 3.59% over the previous year.

From January to September 2026, the company achieved net profit attributable to shareholders of listed companies of 4.586 billion yuan, a year-on-year decrease of 10.90%, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 3.374 billion yuan, an increase of 25.02% over the previous year.

From January to September 2026, the company's net operating cash flow inflow was 5.347 billion yuan, an increase of 127.54% over the previous year, and continued to maintain high-quality development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.